Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Pipeline Review, H2 2018

  • ID: 4590363
  • Drug Pipelines
  • 55 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Ablynx NV
  • Apogenix AG
  • Bristol-Myers Squibb Co
  • GigaGen Inc
  • Incyte Corp
  • Leap Therapeutics Inc
  • MORE
Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Pipeline Review, H2 2018

Summary:

Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) pipeline Target constitutes close to 14 molecules. The latest report Tumor Necrosis Factor Receptor Superfamily Member 18 - Pipeline Review, H2 2018, outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Glucocorticoid induced tumor necrosis factor receptor or TNFRSF18 or AITR is a protein encoded by TNFRSF18 gene. TNFSF18 is involved in interactions between activated T-lymphocytes and endothelial cells and in the regulation of T-cell receptor-mediated cell death. It mediated NF-kappa-B activation via the TRAF2/NIK pathway.

The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 5, 4 and 2 respectively. Report covers products from therapy areas Oncology which include indications Solid Tumor, Melanoma, Non-Small Cell Lung Cancer, Adenocarcinoma Of The Gastro esophageal Junction, Blood Cancer, Endometrial Cancer, Esophageal Cancer, Gastric Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hepatocellular Carcinoma, Lymphoma, Metastatic Melanoma, Metastatic Renal Cell Carcinoma and Transitional Cell Carcinoma (Urothelial Cell Carcinoma).

Furthermore, this report also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18)
  • The report reviews Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted therapeutics
Reasons for Purchase:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Ablynx NV
  • Apogenix AG
  • Bristol-Myers Squibb Co
  • GigaGen Inc
  • Incyte Corp
  • Leap Therapeutics Inc
  • MORE
Introduction

Report Coverage

Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Overview

Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Companies Involved in Therapeutics Development

Ablynx NV

Apogenix AG

Bristol-Myers Squibb Co

Checkpoint Therapeutics Inc

GigaGen Inc

Incyte Corp

Leap Therapeutics Inc

MedImmune LLC

Merck & Co Inc

Novartis AG

OncoMed Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Drug Profiles

AVA-018 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-986156 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CK-302 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Protein to Agonize GITR for Solid Tumor - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GWN-323 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INCAGN-1876 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MEDI-1873 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MK-1248 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MK-4166 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Agonize GITR for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Agonize GITR for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Agonize GITR for Solid Tumors - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OMP-336B11 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TRX-518 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Dormant Products

Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Product Development Milestones

Featured News & Press Releases

Apr 18, 2018 : OncoMed Presents Preclinical Abstract on GITRL-Fc trimer (OMP-336B11) At The 2018 American Association for Cancer Research Annual Meeting

Apr 09, 2018 : OncoMed to Present Multiple Preclinical Abstracts Related to Immuno-Oncology Programs at the 2018 American Association for Cancer Research Annual Meeting

Jan 16, 2018 : Leap Therapeutics Announces First Patient Dosed with TRX518 Combination Therapy in Advanced Solid Tumors Trial

Nov 13, 2017: Leap Therapeutics Provides Update on its Antineoplastic Drug Candidate TRX-

Sep 13, 2017: OncoMed Doses First Patient with GITRL-Fc in Phase 1a Clinical Trial

Apr 05, 2017: OncoMed Highlights Data Presented on GITRL-Fc trimer at the American Association for Cancer Research Annual Meeting

Apr 03, 2017: Leap Therapeutics Presents Non-clinical and Phase 1 Data for TRX518 at the 2017 AACR Annual Meeting

Mar 07, 2017: Agenus Announces Presentation on INCAGN01876 at the American Association for Cancer Research (AACR) 2017 Annual Meeting

Mar 01, 2017: Leap Therapeutics to Present Clinical Data on TRX518 at 2017 AACR Annual Meeting

Nov 12, 2016: Leap Therapeutics Presents Data from Phase 1 Study of GITR Agonist

Jun 22, 2016: Agenus Announces Commencement of Phase 1/2 Clinical Trial of anti-GITR Checkpoint Antibody INCAGN1876 in Patients with Solid Tumors

Jun 05, 2016: Leap Therapeutics Presents Data from Phase 1 Single Dose Safety Study of Anti-GITR Immunotherapy TRX518 in Patients with Advanced Relapsed or Refractory Solid Tumors at American Society of Clinical Oncology (ASCO) 2016 Annual Meeting

Apr 19, 2016: OncoMed Presents GITRL-Fc Research at the AACR Annual Meeting

Apr 18, 2016: Agenus Presents Poster on Checkpoint Antibody Product Candidate INCAGN01876 at the American Association for Cancer Research (AACR) 2016 Annual Meeting

Jan 21, 2016: Agenus Announces Clearance of Investigational New Drug Application by the FDA for anti-GITR Antibody

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Indication, H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pipeline by Ablynx NV, H2 2018

Pipeline by Apogenix AG, H2 2018

Pipeline by Bristol-Myers Squibb Co, H2 2018

Pipeline by Checkpoint Therapeutics Inc, H2 2018

Pipeline by GigaGen Inc, H2 2018

Pipeline by Incyte Corp, H2 2018

Pipeline by Leap Therapeutics Inc, H2 2018

Pipeline by MedImmune LLC, H2 2018

Pipeline by Merck & Co Inc, H2 2018

Pipeline by Novartis AG, H2 2018

Pipeline by OncoMed Pharmaceuticals Inc, H2 2018

Pipeline by Regeneron Pharmaceuticals Inc, H2 2018

Dormant Projects, H2 2018

List of Figures

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Ablynx NV
  • Apogenix AG
  • Bristol-Myers Squibb Co
  • Checkpoint Therapeutics Inc
  • GigaGen Inc
  • Incyte Corp
  • Leap Therapeutics Inc
  • MedImmune LLC
  • Merck & Co Inc
  • Novartis AG
  • OncoMed Pharmaceuticals Inc
  • Regeneron Pharmaceuticals Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll